Timcevibart Biosimilar Monoclonal Antibody (SARS-CoV-2 Spike RBD) for Research

Cat No.: GMP-Bios-INN-1417

Anti-SARS-CoV-2 Spike RBD therapeutic antibody (Pre-made Timcevibart biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture,  assay development,  animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Timcevibart (development codes STE90-C11/COR-101) is a human monoclonal antibody targeting the receptor-binding domain of the SARS-CoV-2 spike protein. It is developed by CORAT Therapeutics for COVID-19. It is in Phase Ib/II clinical development.

Order Information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
Catalog No. Package Price(In USD)
GMP-Bios-INN-1417-1mg 1mg 3090
GMP-Bios-INN-1417-10mg 10mg
GMP-Bios-INN-1417-100mg 100mg
GMP-Bios-INN-1417-xmg ≥100mg



Product Details

Products Name (INN Index) Pre-Made Timcevibart biosimilar, Whole mAb: Anti-SARS-CoV-2 Spike RBD therapeutic antibody
INN Name Timcevibart
Target SARS-CoV-2 Spike RBD
Format Whole mAb
Derivation Human
Species Reactivity Human
CH1+2+3 Isotype G1
VD LC Kappa
Highest_Clin_Trial (Jan '20) TBC
Est. Status Active
100% SI Structure 7b3o:HL
99% SI Structure None
95-98% SI Structure None
Year Proposed 2023
Year Recommended 2024
Companies TBC
Conditions Approved TBC
Conditions Active TBC
Conditions Discontinued TBC
Production na
Development Tech na